RHHBY says the ZUPREME-1 study meets its goal as petrelintide delivers up to 10.7% weight loss with placebo-like tolerability ...

Altruist Biologics, an Innovent Biologics subsidiary and world-class contract development and manufacturing organization (CDMO), recently announced the launch of Altru-CONtm, a high-concentration ...

AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab (SKYRIZI®) ...

Altru-CON harnesses proprietary excipient blends and expertise to maximize drug delivery and stability through high-concentration formulation.The platform can reduce IND timelines to under nine ...

Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-valueAt the maximally effective dose, there were no cases of vomiting and no treatment ...

Three experimental injectable antiretrovirals – a novel capsid inhibitor and two next-generation integrase inhibitors – could ...

Xeris Biopharma benefits from the FDA's CRL to Corcept's relacorilant, removing a major competitive threat to Recorlev sales ...

Orforglipron, a novel oral nonpeptide GLP-1 receptor agonist (RA), led to a greater reduction in A1c and more significant weight loss compared to oral semaglutide in patients with type 2 diabetes (T2D ...

Efgartigimod alfa–hyaluronidase significantly improves ocular symptoms in adults with ocular myasthenia gravis, according to phase 3 trial data.

Petrelintide achieved up to 10.7% mean body weight reduction at week 42 (versus 1.7% with placebo) and demonstrated placebo-like tolerability At the maximally effective dose, there were no cases of ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Ascendis Pharma’s Yuviwel (navepegritide) for ...

Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value– At the maximally effective dose, there were no cases of vomiting and no treatment ...